GlaxoSmithKline Recently Made `Very Casual' Overture to Genzyme, WSJ Says
GlaxoSmithKline Plc recently made a “very casual” overture to Genzyme Corp., asking the biotechnology company to keep it in mind if Genzyme considered selling itself, the Wall Street Journal reported, citing an unidentified person familiar with the matter.
The companies didn’t extend that dialogue, the newspaper said. Glaxo declined to comment, the Journal said.
Genzyme, which hasn’t decided whether it wants to sell itself, is considering an informal offer from Sanofi-Aventis SA, the newspaper said, citing unidentified people familiar with the matter.